



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Laszlo Czollner et al.

Attorney Docket: SAN1011US

Serial No.:

10/573,517

Filed:

March 24, 2006

For:

NOVEL DERIVATIVES OF

4A,5,9,10,11,12-HEXAHYDROBENZOFURO[3A,3,2][2]-

BENZAZEPINE, METHOD FOR THE PRODUCTION THEREOF AND

USE THEREOF IN THE PRODUCTION OF MEDICAMENTS

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith are the following:

- 1. Supplemental Information Disclosure Statement (2 pages);
- 2. Form 1449 listing 9 documents (1 page); and
- 3. Copies of the listed documents.

Please charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-2312.

Dated: 411/13, 2006

Respectfully submitted,

Customer No. 009561

Patrick J. O'Connell (33,984)

POPOVICH, WILES & O'CONNELL, P.A.

650 Third Avenue South, Suite 600

Minneapolis, MN 55402

Telephone: (612) 334-8989

Attorney for Applicants

Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. EV 769991635 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: <u>April 13, 2006</u>

Signature:

Name: Jodi June



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Laszlo Czollner et al.

Attorney Docket: SAN1011US

Serial No.:

10/573,517

Filed:

March 24, 2006

For:

NOVEL DERIVATIVES OF

4A,5,9,10,11,12-HEXAHYDROBENZOFURO[3A,3,2][2]-

BENZAZEPINE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF IN THE PRODUCTION OF MEDICAMENTS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to Sections 1.56, 1.97, and 1.98 of Title 37 of the Code of Federal Regulations, the following information is set forth in compliance with Applicants' duty of disclosure, as well as the duty of others substantively involved in the preparation of the above-titled application.

The Applicants and others substantively involved in the preparation of the application are aware of the documents listed on the enclosed PTO-1449 form. Copies of the non-U.S. documents are enclosed. International Application No. PCT/AT2004/00251, published as WO 2005/030332 A2, has entered the United States national phase as U.S. Serial No. 10/537,568. This application and the subject application both claim priority of Austrian Patent Application No. A 1538/2003.

Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. EV 769991635 US in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: <u>April 13, 2006</u>

Signature:

Name: Jody Jung

Supplemental Information Disclosure Statement

Applicants: Laszlo Czollner et al. Serial Number: To Be Assigned

re Statement Attorney Docket: SAN1011US

The present statement reflects the direct knowledge of the undersigned and information disclosed to the undersigned by the Applicants and others substantively involved in the preparation of the present application pursuant to their duty under 37 C.F.R. § 1.56.

Applicants reserve the right to show, pursuant to 37 C.F.R. § 1.131 or otherwise, that any one or more of the documents listed on the PTO-1449 form is not prior art to the present invention.

Pursuant to the Manual of Patent Examining Procedure, Chapter 609,
Applicants request that the Examiner consider each of the listed documents and initial
and return to the undersigned a copy of the enclosed PTO-1449 form.

It is believed that no fees are due in connection with this submission. However if this is incorrect, please charge any additional fees to Deposit Account Number 16-2312.

Respectfully submitted,

Date: April 15, WO6

Customer No. 009561

Patrick J. O'Connell (33,984)

POPOVICH, WILES &

O'CONNELL, P.A.

650 Third Avenue South, Suite 600

Minneapolis, MN 55402 Telephone: (612) 334-8989 Attorney for Applicants

D.E.	
FQRM PT	O-1449
\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	
APR 1.3 2006 M	INFO
_ \	STA
THE REPORT OF	(Use s
TRADEMARK	(

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	SERIAL NO.
SAN1011US	10/573,517
APPLICANTS	<u> </u>
Laszlo Czollner et al.	
FILING DATE	GROUP
March 24, 2006	
Laszlo Czollner et al.	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DO	сим	ENT I	NUME	BER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
											· -

FOREIGN PATENT DOCUMENTS

 DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	ATION NO
WO 2005/030332 A2	04/07/05	WIPO			Х	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

with Acetylcholinesterase from <i>Torpedo californica</i> : Implications for the Design of New Anti-Alzheimer Drugs," <i>PROTEINS</i> : Structure, Function and Genetics, 42(2):182-191 (2001). Bastida et al., "Alkaloids from <i>Narcissus Leonensis</i> ," <i>Phytochemistry</i> , Pergamon Press	Bhandarkar et al., "Structure and Biosynthesis of Chlidanthine," <u>Journal of the Chemical Society</u> , Section C: Organic Chemistry, Chemical Society. Letchworth, GB,
with Acetylcholinesterase from <i>Torpedo californica</i> : Implications for the Design of New Anti-Alzheimer Drugs," <i>PROTEINS</i> : Structure, Function and Genetics, 42(2):182-191 (2001). Bastida et al., "Alkaloids from <i>Narcissus Leonensis</i> ," <i>Phytochemistry</i> , Pergamon Press	no. 9, pages 1224-1227 (1970).
	Bastida et al., "Alkaloids from <i>Narcissus Leonensis</i> ," <u>Phytochemistry</u> , Pergamon Press, GB, 34(6):1656-1658 (1993).
Li et al., "Alkaloids of <i>Lycoris guangxiensis</i> ," <u>Planta Medica</u> , Thieme, Stuttgart, DE, 53(3):259-261 (1987).	
Mutschler et al., "Arzneimittelwirkungen," 2001, WVG, Stuttgart, page 195, column 2, paragraph 1.	paragraph 1.
Pilger et al., "Accurate Prediction of the Bound Conformation of Galanthamine in the Active Site of <i>Torpedo californica</i> Acetylcholinesterase Using Molecular Docking," <u>Journal of Molecular Graphics and Modelling</u> , Elsevier Science, New York, NY, US, 19(3/4):288-296 (2001).	Active Site of <i>Torpedo californica</i> Acetylcholinesterase Using Molecular Docking," <u>Journal of Molecular Graphics and Modelling</u> , Elsevier Science, New York, NY, US, 19(3/4):288-296 (2001).
Recanatini et al., "Acetylcholinesterase Inhibitors in the Context of Therapeutic Strategies to Combat Alzheimer's Disease," Expert Opinion on the Therapeutic Patents , Ashley Publications, GB, 12(12):1853-1865 (2002).	 Strategies to Combat Alzheimer's Disease," Expert Opinion on the Therapeutic
Vlahov et al., "Synthesis of Galanthamine and Related Alkaloids-New Approaches. I", Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, 45(11):3329-3345 (1989).	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.